193 related articles for article (PubMed ID: 37549291)
21. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
22. Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes.
Sakthikumar S; Roy A; Haseeb L; Pettersson ME; Sundström E; Marinescu VD; Lindblad-Toh K; Forsberg-Nilsson K
Genome Biol; 2020 Jun; 21(1):127. PubMed ID: 32513296
[TBL] [Abstract][Full Text] [Related]
23. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
24. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
[TBL] [Abstract][Full Text] [Related]
25. Identification of PBK as a hub gene and potential therapeutic target for medulloblastoma.
Deng Y; Wen H; Yang H; Zhu Z; Huang Q; Bi Y; Wang P; Zhou M; Guan J; Zhang W; Li M
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35593307
[TBL] [Abstract][Full Text] [Related]
26. Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development.
Aref D; Moffatt CJ; Agnihotri S; Ramaswamy V; Dubuc AM; Northcott PA; Taylor MD; Perry A; Olson JM; Eberhart CG; Croul SE
Brain Pathol; 2013 Mar; 23(2):178-91. PubMed ID: 22966790
[TBL] [Abstract][Full Text] [Related]
27. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis.
Vo DT; Subramaniam D; Remke M; Burton TL; Uren PJ; Gelfond JA; de Sousa Abreu R; Burns SC; Qiao M; Suresh U; Korshunov A; Dubuc AM; Northcott PA; Smith AD; Pfister SM; Taylor MD; Janga SC; Anant S; Vogel C; Penalva LO
Am J Pathol; 2012 Nov; 181(5):1762-72. PubMed ID: 22985791
[TBL] [Abstract][Full Text] [Related]
28. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration.
Yuan L; Zhang H; Liu J; Rubin JB; Cho YJ; Shu HK; Schniederjan M; MacDonald TJ
Mol Cancer; 2013 Mar; 12():18. PubMed ID: 23497290
[TBL] [Abstract][Full Text] [Related]
29. The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity.
Laneve P; Po A; Favia A; Legnini I; Alfano V; Rea J; Di Carlo V; Bevilacqua V; Miele E; Mastronuzzi A; Carai A; Locatelli F; Bozzoni I; Ferretti E; Caffarelli E
Oncotarget; 2017 May; 8(19):31003-31015. PubMed ID: 28415684
[TBL] [Abstract][Full Text] [Related]
30. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
31. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
32. Clinical and mutational profiles of adult medulloblastoma groups.
Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
[TBL] [Abstract][Full Text] [Related]
33. DTI fiber tractography of cerebro-cerebellar pathways and clinical evaluation of ataxia in childhood posterior fossa tumor survivors.
Oh ME; Driever PH; Khajuria RK; Rueckriegel SM; Koustenis E; Bruhn H; Thomale UW
J Neurooncol; 2017 Jan; 131(2):267-276. PubMed ID: 27785688
[TBL] [Abstract][Full Text] [Related]
34. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
Richardson S; Hill RM; Kui C; Lindsey JC; Grabovksa Y; Keeling C; Pease L; Bashton M; Crosier S; Vinci M; André N; Figarella-Branger D; Hansford JR; Lastowska M; Zakrzewski K; Jorgensen M; Pickles JC; Taylor MD; Pfister SM; Wharton SB; Pizer B; Michalski A; Joshi A; Jacques TS; Hicks D; Schwalbe EC; Williamson D; Ramaswamy V; Bailey S; Clifford SC
Neuro Oncol; 2022 Jan; 24(1):153-165. PubMed ID: 34272868
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma genomics in the modern molecular era.
Kumar R; Liu APY; Northcott PA
Brain Pathol; 2020 May; 30(3):679-690. PubMed ID: 31799776
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
37. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
38. Differentiation of pilocytic astrocytoma, medulloblastoma, and hemangioblastoma on diffusion-weighted and dynamic susceptibility contrast perfusion MRI.
Kurokawa R; Kurokawa M; Baba A; Kim J; Capizzano A; Bapuraj J; Srinivasan A; Moritani T
Medicine (Baltimore); 2022 Nov; 101(44):e31708. PubMed ID: 36343086
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
[TBL] [Abstract][Full Text] [Related]
40. Medulloblastomics: the end of the beginning.
Northcott PA; Jones DT; Kool M; Robinson GW; Gilbertson RJ; Cho YJ; Pomeroy SL; Korshunov A; Lichter P; Taylor MD; Pfister SM
Nat Rev Cancer; 2012 Dec; 12(12):818-34. PubMed ID: 23175120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
